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PneumoniaAbstract Background: Hospital acquired pneumonia occurs more than 48 h after hospital admis-
sion and was not present at the time of admission, while ventilator associated pneumonia occurs
after 48–72 h of endotracheal intubation or within 48 h of extubation. HAP is the second most com-
mon nosocomial infection and accounts for approximately 25% of all infections in the Intensive
Care Unit worldwide.
Purposes: To identify the etiology, initial evaluation, prevention, and treatment of adult patients
with ICU HAP, and VAP in Suez Canal University hospital and their management strategies.
Methods: This study was conducted in the department of ICU, Suez Canal University Hospital;
Ismailia, Egypt in the period from May to August 2013. All the patients were subjected to clinical
and radiological assessment, Endotracheal aspirate samples for culture, and sensitivity to determine
the causative organisms, Clinical Pulmonary Infection Score was done in order to determine the
severity of HAP.
Results: 89% of patients were suffering from VAP, while 11% were suffering from HAP, with
mean age of 63.8 ± 10.47 years. Methicillin-resistant Staphylococcus aureus, and Klebsiella pneumo-
niae represented the most common isolated organisms that accounted about 65% of the studied
population. The isolated microorganisms were resistant to Amoxicillin, MRSA showed highest
sensitivity (44.4%) to Vancomycin and (27.8%) to Imipenem. K. pneumoniae were sensitive mainly
to Imipenem (75.9%) and to Levoﬂoxacin (44.8%).
Conclusion: Gram-negative organisms were isolated in 46% of cases, gram-positive organisms in
41% and the isolated organisms showed high resistance to most of the tested antibiotics.
ª 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of The Egyptian Society of Chest
Diseases and Tuberculosis. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).rculosis.
Table 1 Modiﬁed Clinical Pulmonary Infection Score (CPIS)
chart.
Diagnostic
feature
CPIS points
0 1 2
Tracheal
secretions
Rare Abundant Abundant and
purulent
Chest
radiograph
inﬁltrate
None Diﬀuse Localized
Temperature
(C)
P36.5
and 638.4
P38.5
and 638.9
P39 or 636
White blood
cells (·109/L)
P4.0 or
611.0
<4.0 or
>11.0
<4.0 or >11.0 plus
band forms P0.5
PaO2/FiO2
mmHg
>240 or
ARDS
6240 and no ARDS
Microbiology Negative Positive Positive plus positive
Gram stain
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Hospital-acquired pneumonia (HAP) is considered one of the
most common nosocomial infections which accounts for
approximately 25% of all infections in the intensive care unit
(ICU) [1].
The difference between HAP and community acquired
pneumonia (CAP) is the susceptibility of patients with HAP to
pneumonia from different and potentially virulent pathogens [2].
While, HAP is closely related to ventilator-associated pneu-
monia (VAP) that refers to pneumonia that arises more than
48–72 h after endotracheal intubation, and the cause of infec-
tion is multidrug-resistant (MDR) bacteria [3].
There are many risk factors associated with HAP, and VAP
and the presence of environmental and pharmacological
factors [4].
The diagnosis of HAP is mainly diagnosed clinical through
the endotracheal aspirate (ETA) cultures, white blood cell
(WBC) count, serial chest radiographs, and arterial blood
gases (ABG) [5].
The treatment of HAP started with broad-spectrum empiric
antibiotics; then shifted to narrow-spectrum speciﬁc therapy to
minimize the risk of resistance and adverse drug reactions over
the treatment period, guided by microbiological results due to
that the precise pathogen of HAP is usually unknown [6]. So,
each ICU should design its own scheme for treatment on the
basis of their microbiological results which has a major impact
on patients’ morbidity, mortality, and the economic aspect of
their treatment [7].
We therefore aimed to identify the etiology, initial evalua-
tion, prevention, and treatment of adult patients with ICU
HAP, and VAP in Suez Canal University hospital (SCU) as
well as the proper management strategies of patients with
ICU HAP, and VAP.
Patients & methods
Patients
This study was conducted on 100 patients admitted to the
department of ICU, SCU Hospital; Ismailia, Egypt who devel-
oped HAP or VAP during the period from May 2013 to
October 2013 with an inclusion criteria of age range from 18
to 81 years old, of both sexes, showing symptoms & signs of
pneumonia (productive cough with purulent sputum, and fever
P38 C, or hypothermia 636.3 C).
With chest radiography showing newly developed signs of
pneumonia (opacity of one lung segmental lobe, or bilateral
opacities primarily in the bases of the lungs). HAP occurs more
than 48 h after hospital admission, but was not present at the
time of admission. VAP occurs after 48–72 h of endotracheal
intubation.
We excluded patients with lung tumor, trauma, collapse,
heart failure, pulmonary edema, patients with no radiographic
shadows suggestive of pneumonia and or Neonates/pediatrics
patients.
Methods
All patients were subjected to full history taking, clinical exam-
ination, laboratory investigations in the form of Completeblood count (CBC), arterial Blood Gases (ABG) {Roche
OMNI C blood gases machine, made in Japan for Siemens
Medical System, Inc, Issaquah, WA98029-7002USA},
Endotracheal aspirate (ETA) in order to make culture and
sensitivity to determine the causative organisms.
All specimens were inoculated onto Blood agar,
MacConkey agar, Mannitol salt agar, Chocolate agar, and
Muller Hinton agar, incubated at 37 C for 24 h. Gram stain
and susceptibility test were performed to all specimens in
order to diagnose the causative organism. Bacterial growth
in these specimens is then quantitated and deﬁned by the
presence of bacteria above the predetermined threshold con-
centration (BAL >104 colony forming units [CFU]/ml).
Plain posteroanterior and/or anteroposterior chest X-ray
was performed to conﬁrm the diagnosis, that showed newly
developed evidence of pneumonia (opacity of one lung
segmental lobe, or bilateral opacities primarily in the bases
of the lungs).
The protocol of empiric antibiotic treatment employed in
the SCU hospital before the culture results is to give
Ceftazidime 1 g twice daily, plus Ampicillin/Sulbactam 1.5 g
3 times a day was given to 79% of the patients on admission
to cover the most vulnerable gram positive, and gram negative
microorganisms.
The Severity of HAP & VAP was assessed using
Modiﬁed Clinical Pulmonary Infection Score (CPIS) [8]
(Table 1).
Patients should have their CPIS recalculated daily, if the
CPIS is less than 6, infection is unlikely and the decision to
treat with antibiotics should be carefully considered.
Statistical analysis
Values are shown throughout the manuscript as number and
percent as well as mean and standard deviation (SD).
Results were compared using the Student t-test. A P-value
equal or less than 0.05 was considered signiﬁcant in all
statistical tests. Statistical analyses and data blotting were
performed using Microsoft excel by Microsoft Inc. and SPSS
(SPSS 20.0 by SPSS software Inc.).
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The study work got approval from the Ethics Committee of
Faculty of Medicine, Suez Canal University (FOMSCU);
Ismailia, Egypt.Table 2 Demographic data of the studied patients.
Speciﬁcation Freq. (n= 100) %
Age 665 years 77 77
>65 years 23 23
Sex Male 73 73
Female 27 27
Table 3 Clinical data of the studied patients.
Speciﬁcation
Concomitant illness Diabetes mellitus (DM)
Hypertension
Ischemic heart disease (IHD
Chronic obstructive pulmo
DM+Hypertension
DM+Hypertension + IH
DM+ IHD+ COPD
Hypertension + COPD
OTHERS
NONE
Cause of ICU admission Acute myocardial infarctio
Cor pulmonale
Acute respiratory distress s
Motor car accident
Decompensated heart failu
Cerebrovascular accident
OTHERS
Onset of pneumonia Early (64 days)
Late (>4 days)
Severity of pneumonia Mild
Moderate
Severe
Antibiotics given on admission Ceﬁpime
Ceftazidime
Levoﬂoxacin
Cefoperazone + Amp/Sulb
Ceftazidime + Ampicillin/S
Levoﬂoxacin + Imipenem
Ceﬁpime + Amp/Sulb
Levoﬂoxacin + Clindamyc
Ceftazidime + Ceﬁpime
Ceftriaxone + Levoﬂoxacin
Meropenem + Clindamycin
Cipro + Erythromycin + C
Smoking Smokers
Non smokers
Mechanical ventilation Ventilated
Non ventilated
Fate of the patients Discharged
DiedResults
Results are mentioned in Tables 2–10.
Discussion
This study was conducted on 100 cases admitted to the depart-
ment of ICU, SCU Hospital; Ismailia, Egypt who developed
HAP or VAP during the period from May to October 2013,
to investigate the etiology, prevention, initial evaluation, and
treatment in order to identify the proper management strate-
gies of these patients. The mean age of the patients was
63.8 ± 10.47 years with an range from 18 to 81 years, this
was comparable to the mean age of the patients included in
a study conducted by Holzapfel et al. [9] who recognized thatFreq. (n= 100) %
4 4
9 9
) 3 3
nary disease (COPD) 4 4
24 24
D 11 11
2 2
1 1
11 11
31 31
n 3 3
4 4
yndrome (ARDS) 10 10
24 24
re 5 5
21 21
32 32
17 17
83 83
18 18
47 37
35 35
7 7
2 2
3 3
2 2
ulb 79 79
1 1
1 1
in 1 1
1 1
1 1
1 1
eﬁpime 1 1
48 48
52 52
89 89
11 11
37 37
63 63
Table 4 The relation between the isolated organisms and the
mechanical ventilation.
Isolated organisms Total
No.
Mechanical ventilation (n= 100)
Ventilated
(VAP)
Non ventilated
(HAP)
Freq. % of
column
Freq. % of
column
Methicillin resistant
Staph.aureus (MRSA)
36 32 35.9 4 36.35
Klebsiella pneumoniae 29 25 28.1 4 36.35
Pseudomonas
aeruginosa
6 5 5.7 1 9.1
Proteus spp. 6 6 6.8 0 0.0
E. coli 5 5 5.6 0 0.0
Strept. viridans 3 2 2.2 1 9.1
Methicillin sensitive
Staph.aureus (MSSA)
2 2 2.2 0 0.0
No growth 13 12 13.5 1 9.1
Total 100 89 100 11 100
P value = 0.88.
Table 6 The relation between the detected organisms and the
age.
Isolated organisms Total
No
Age
665 years >65 years
Freq. % of
column
Freq. % of
column
MRSA 36 30 39 6 26.3
Klebsiella pneumoniae 29 20 25.9 9 39.3
Pseudomonas
aeruginosa
6 5 6.5 1 4.3
Proteus spp. 6 5 6.5 1 4.3
E. coli 5 4 5.1 1 4.3
Strept. viridans 3 1 1.3 2 8.6
Methicillin sensitive
Staph.aureus (MSSA)
2 2 2.6 0 0.0
No growth 13 10 13.1 3 12.9
Total 100 77 100.0 23 23.0
P value = 0.29.
628 M. Eida et al.pneumonia is more likely to develop in the elderly period and
paid attention to the rising rate of mortality from pneumonia
with extreme of ages.
The main obstacles we faced in this study are the limited
number of available ICU beds, prolonged patient admission
time due to their primary illness, and the superadded admis-
sion time due to their HAP. Also, the inability to culture
important causative microorganisms such as Legionella pneu-
mophila,Mycoplasma pneumoniae, and Chlamydia pneumoniae,
as well as fungal and viral microorganisms due to ﬁnancial
shortage, and difﬁculty of the procedures.
For the microbiological results of the VAP group, we found
that 35.9% of patients were infected by MRSA, followed by
Klebsiella pneumoniae (28.1%), Proteus species (6.8%),
Pseudomonas aeruginosa (5.7%), Escherichia coli (5.6%),
Streptococcus viridans (2.2%), and Methicillin sensitive
Staph.aureus (MSSA) (2.2%) (Table 4). Mechanical ventilation
is associated with high rates of HAP because the endotracheal
tube bypasses upper respiratory tract defenses, allows forTable 5 The relation between the detected organisms and the sever
Isolated organisms Total No. Severity of
Mild
Freq. %
MRSA 36 2
Klebsiella pneumoniae 29 6
Pseudomonas aeruginosa 6 1
Proteus spp. 6 4
E. coli 5 3
Strept. viridians 3 0
Methicillin sensitive Staph.aureus (MSSA) 2 0
No growth 13 2
Total 100 18 1
P value = 0.007.pooling of oropharyngeal secretions, prevents effective cough,
and infection. Likely Samah et al. [12] studied HAP in the ICU
of Police Hospitals and found that the most common isolated
organisms were MRSA (22%) followed by Acinetobacter
species (20%), K. pneumoniae (18%), P. aeruginosa (15%).
While in the non-ventilated HAP group, the results revealed
that MRSA, and K. pneumoniae are equally isolated (36.35%),
followed by P. aeruginosa (9.1%), and Streptococcus viridans
(9.1%) (Table 4). El Solh et al. [10] study agreed with our
results in that the most frequent causes of HAP were
MRSA (33%), gram-negative enteric bacilli (24%), and
Pseudomonas species (14%).
Our research showed partial agreement with the study con-
ducted by Queenan et al. [11] which revealed that Pseudomonas
aeruginosa and Klebsiella species were the most prevalent
organisms in the pathogenesis of HAP, and together they
accounted for approximately half of all organisms. Also we
found partially agreement with the results of Maha et al. [13]
who studied the diagnostic value of BAL in VAP of pediatric
patients, and Hassan et al. [14].ity of pneumonia.
pneumonia (n= 100)
Moderate Severe
of column Freq. % of column Freq. % of column
11.1 18 38.3 16 45.7
33.3 17 36.2 6 17.1
5.6 1 2.1 4 11.4
22.2 1 2.1 1 2.9
16.7 0 0.0 2 5.8
0.0 3 6.4 0 0.0
0.0 2 4.2 0 0.0
11.1 5 10.8 6 17.1
00.0 47 100.0 35 100.0
Hospital acquired pneumonia & intensive care unit 629The signiﬁcantly high rate of gram-negative bacilli in our
work and many other studies probably indicates the high inci-
dence of prolonged hospital stay and the prolonged duration
of mechanical ventilation that predisposes the patients to
acquire infections from the MDR pathogens.
Magdy et al. [15] studied HAP in ﬁve major Egyptian
Military Hospitals (Kobbry El kobba, El-Maadi, Masr
Elgadida, El-Galaa and Ghamra) and reported that gram
negative organisms were the most prevalent in HAP especially
K. pneumoniae (23.1%), followed by P. aeruginosa (17.3%),
and E. coli (11.5%), while Staphylococcus haemolyticus
(7.7%) was the most prevalent gram positive organism.
Patra et al. [16] reported that VAP constituted 76% of
patients with HAP and represented the most frequent nosoco-
mial infection in the ICU (80%), with an overall mortality of
HAP reaching 60%; all were secondary to gram-negative
infections with P. aeruginosa contributing to 57.1% of deaths
followed by K. pneumoniae, E. coli and Acinetobacter species.
The increasing incidence of infections caused by MDR patho-
gens contributes to the emerging seriousness of these infections
with expected higher mortality rate.
In contrast, other authors reported other bacterial strains.
Amal et al. [17] who studied 160 patients having pneumonia
in both Cairo and Tanta University Hospitals, of which only
7.5% of them having HAP, found that two major organisms
were responsible for HAP; namely Streptococcus pneumoniae
and K. pneumoniae; 33.3% for each, followed by Hemophilus
inﬂuenzae and Streptococcus pyogenes; 11.1% for each, this
difference may be due to the small number of patients with
HAP in their study.Table 7 The relation between concomitant illness and the severity
Concomitant illness Total No. Severity of pneumonia
Mild
Freq. % of column
DM 41 2 11.1
COPD 7 3 16.7
OTHERS 21 3 16.7
NONE 31 10 55.5
Total 100 18 100.0
P value = 0.04.
Table 8 The relation between the isolated organisms and the sensit
Isolated organisms Tested antibiotic
Vancomycin
(%)
Imipenem
(%)
Levoﬂo
(%)
MRSA 44.4 27.8 11.1
Klebsiella spp. 3.4 75.9 44.8
P. aeruginosa 66.7 50 66.7
Proteus spp. 50 16.7 33.3
E. coli 0 80 40
Strept. Viridians 0 66.7 33.3
Methicillin sensitive Staph.aureus
(MSSA)
0 0 0
P value = 0.32.Also unlikely to this study, Nadia et al. [18] were studying
the atypical bacteria in the ICU of Critical Care Department in
the Alexandria Main University Hospital, and found that
Candida species was the commonest isolated organism
accounting for 23.3%, followed by P. aeruginosa (21.6%), then
the polymicrobial growth (20%), Staphylococcus aureus
(16%), Acinetobacter species (8.3%), Proteus species 6.6%,
Klebsiella species (6.6%), E. coli (5%), Coagulase-negative sta-
phylococci (1.6%), and Diphtheroids (1.6%). It is also to be
noted that 31.6% of the total ETA of the 60 VAP cases were
negative by the conventional microbiological culture.
Antibiotic therapy and critical illness can suppress the
normal bacterial ﬂora and lead to an over-growth of
Enterobacteriaceae like K. pneumoniae in the respiratory tract.
The most concerning is the acquisition of ESBL that render the
bacteria resistant to penicillin and cephalosporin antibiotics,
and may cause serious nosocomial infections especially in criti-
cally ill patients. Laurent et al. [19] have described numerous
outbreaks with ICU-acquired ESBL-producing K. pneumoniae,
where infection increased from a baseline rate of 0.44 cases per
1000 patient days to 6.86 cases per 1000 patient-days.
We found that about 13% of ETA showed that no growth
on routine culture, so polymerase chain reaction (PCR) reac-
tion is recommended for these cases in the future studies
according to the ﬁnding of Nadia et al. [18] that found positive
PCR results for atypical bacteria in 9 (15%) out of 60 samples,
5 were positive for M. pneumoniae, 3 for L. pneumophila, and
only 1 was positive for C. pneumoniae, and concluded that
atypical bacteria are not an uncommon cause for HAP, and
VAP.of pneumonia (N = 100).
Moderate Severe
Freq. % of column Freq. % of column
23 48.9 18 51.4
3 6.4 1 2.9
10 21.3 7 20.0
11 23.4 9 25.7
47 100.0 35 100.0
ivity to the tested antibiotics.
xacin Ceftriaxone
(%)
Cefoperazone
(%)
Cefotaxime
(%)
Amoxicillin
(%)
8.3 19.4 8.3 0
13.8 3.4 0 0
0 0 0 0
83.3 16.7 33.3 0
20 20 0 0
33.3 0 0 0
0 0 0 0
630 M. Eida et al.Compared to the study conducted by Ibrahim et al. [20] who
studied the microbiology of HAP in elderly patients in a com-
munity hospital in the Pulmonary and Critical Care Medicine
Division at Washington University, School of Medicine found
that in early onset HAP, the so called main pathogens include
community pathogens such as MSSA, S. pneumoniae and
H. inﬂuenzae as well as gram-negative enteric bacilli are
predominate. While in late onset HAP; MRSA, P. aeruginosa
and K. pneumoniae are frequently encountered.
On the other hand, in this study 24% of enrolled patients
with HAP were admitted primarily to the ICU due to MCA,
followed by 21% due to CVA, compared to Ibrahim et al.
[20] study who conducted a comparative analysis of patients
with early-onset versus late-onset ICU HAP, and found the
primary cause of admission is IHD (32.1%), followed by
CVA (24.2%), then ARDS (19.2%).
Severe concomitant illness predisposes patients in the ICU
to the development of HAP, and contributes to the associated
high mortality rates, as in this study more than third of the
patients had pre-existing illnesses, with DM being the most
common, and the combination of DM and hypertension in
24% of patients (Table 7), that agrees with El Solh et al. [10]Table 9 The relation between used antibiotics before ICU
admission, and the isolated organisms (N= 29).
Used antibiotic Number % Isolated organism
Ceftriaxone 3 21.4% MRSA
Cefotaxime 3 21.4% MRSA
Levoﬂoxacin 3 21.4% Klebsiella spp.
Ciproﬂoxacin 2 14.4% MRSA
Azithromycin 3 21.4% MRSA
Total 14 100%
Unknown antibiotics 15 46.7% MRSA
40% Klebsiella spp.
13.3% P. aeruginosa
Total 15 100%
Table 10 Relation between causative organisms and fate of
the patients.
Isolated organisms No. Fate (n= 100)
Discharged Died
Freq. % of
column
Freq. % of
column
MRSA 36 6 16.2 30 47.7
Klebsiella pneumoniae 29 12 32.4 17 26.9
P. aeruginosa 6 1 2.7 5 7.9
Proteus spp. 6 5 13.5 1 1.6
E. coli 5 4 10.9 1 1.6
Strept. viridans 3 2 5.4 1 1.6
Methicillin sensitive
Staph.aureus (MSSA)
2 2 5.4 0 0
No growth 13 5 13.5 8 12.7
Total 100 37 100 63 100
P value = 0.004.study that found that 72% had at least the same two
concomitant illnesses, while 23% had 3 or more concomitant
illnesses.
Resistance to antibiotics is rapidly evolving. In this study,
the isolated microorganisms are totally resistant to
Amoxicillin. MRSA showed highest sensitivity (44.4%) to
Vancomycin, then (27.8%) to Imipenem, while it was almost
resistant to all other tested antibiotics. K. pneumoniae were
sensitive mainly to Imipenem (75.9%), then to Levoﬂoxacin
(44.8%), and also almost resistant to all other tested antibi-
otics (Table 8). This was in agreement with Gamal Agmy
et al. [21] who conducted their study in Upper Egypt and
found that the causative organisms of HAP were MRSA
(23%), K. pneumoniae (14%), and polymicrobial (12%). A
higher sensitivity was recorded for vancomycin, ciproﬂoxacin,
and moxiﬂoxacin. Very high resistance was recorded for
b-lactam-b-lactamase inhibitors and cephalosporins.
In our research, the mortality rate was 63%, mortality asso-
ciated with HAP due to MRSA was 47.7%, and 26.9% for
HAP due to K. pneumoniae, followed by 7.9% in HAP due
to P. aeruginosa (Table 10).
The prognosis for HAP caused by gram-negative bacilli is
worse than HAP caused by gram-positive pathogens, death
rates associated with P. aeruginosa are particularly high, rang-
ing from 70% to more than 80% in several studies, according
to Garnacho-Montero et al. [22] who found that the mortality
associated with P. aeruginosa or Acinetobacter pneumonia was
87% compared with 55% for pneumonias due to other organ-
isms. While in cases caused by gram-positive pathogens, com-
paring VAP due to MRSA or MSSA, mortality was found to
be directly attributable to pneumonia for 86% of the former
causes versus 12% of the latter, with a relative risk of death
equal to 20.7 for MRSA pneumonia.
Also Chawla [23] admitted higher frequencies of mortalities
associated with MRSA, Enterobacter species, and P. aerugi-
nosa, in a 6-year surveillance study from the period 2002 to
2007 involving ICUs in Latin America, Asia, Africa, and
Europe, using the CDC National Nosocomial Infections
Surveillance (NNIS) deﬁnitions, also reported higher rates of
HAP, and VAP than those of comparable United States ICUs.Conclusion
The Gram-negative organisms were isolated in 46% of cases,
gram-positive organisms were isolated in 41% and the isolated
organisms showed high resistance to most of the tested
antibiotics.
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